

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



微創醫療科學有限公司\*

*(Incorporated in the Cayman Islands with limited liability)*

(Stock code: 00853)

## VOLUNTARY ANNOUNCEMENT

### UPDATES ON THE PROPOSED STRATEGIC RESTRUCTURING OF THE CRM BUSINESS

References are made to the announcements of MicroPort Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 16 July 2025 and 29 September 2025 in relation to the proposed restructuring of the CRM business of the Group (the “**Announcements**”). Unless otherwise specified, capitalised terms used herein shall have the same meanings as used in the Announcements.

The board of directors of the Company (the “**Board**”) is pleased to announce that the independent shareholders of MicroPort CardioFlow have approved the Merger Agreement and the transactions contemplated thereunder at the extraordinary general meeting of MicroPort CardioFlow held on 15 December 2025. It is expected that the Merger will be completed on or about 19 December 2025, upon which all the existing issued shares (including ordinary and preferred shares) of CRM Cayman will be cancelled in exchange for ordinary shares in MicroPort CardioFlow and CRM Cayman will become a wholly-owned subsidiary of MicroPort CardioFlow.

The strategic Merger is a key initiative for the Company to optimize resource allocation and enhance overall competitiveness, aiming to comprehensively strengthen the synergies between the two parties in the field of structural heart disease and the CRM. By integration of complementary product lines and global channel resources, the Company will accelerate market penetration and improve operational efficiency; relying on matured overseas teams and infrastructure, we will further optimize localized service capabilities and supply chain resilience.

At the same time, based on the accumulated expertise in structural heart disease business in interventional therapy, precision delivery and materials platforms, as well as the technical advantages of the CRM business in the fields of AI diagnosis and algorithms, the Company will strongly enter into heart failure, the most promising strategic stronghold in cardiovascular diseases, and expand its business layout with high quality. In this way, the Company will build a comprehensive management plan covering the entire causes, stages, and processes of heart failure, and provide complete heart failure management services for different pathogenic factors, stages of diseases, and the whole processes of “monitoring-diagnosis-treatment-management”. In the long run, the Group is committed to building a professional platform with the world’s largest and most complete product portfolio in the field of heart failure, and is determined to become an emerging technology leader in the field of heart failure diagnosis and treatment, being driven by continuous technological innovation. This initiative will significantly strengthen the Group’s position in the field of diagnosis and treatment of heart failure, which has great development potential, thereby comprehensively enhancing its overall competitiveness in the field of cardiovascular devices.

The Merger will also significantly optimize the structure of consolidated financial statement of the Group. Prior to the Merger, the repurchase obligation for preferred shares arising from historical financing arrangements of the CRM business was reflected as a financial liability in the consolidated statements of the Group. Upon completion of the Merger, these preferred shares will be converted into ordinary shares in MicroPort CardioFlow, and the corresponding repurchase obligation of approximately US\$260 million and related interest burden will be removed from the consolidated statements of the Group, effectively reducing the overall debt scale and financial costs of the Group with the reduction of the liabilities to assets ratio.

In addition, prior to the Merger, convertible bonds with the original principal amount of approximately US\$128 million of CRM Cayman had been refinanced, and together with accrued interest, were replaced by a medium- and long-term bank loan with an annual interest rate of 2.8% (adjusted annually based on LPR and agreed floating points and calculation method). Such pre-Merger debt structure optimization, together with the release of the preferred share repurchase obligation after the Merger, will jointly optimize the consolidated financial statements of the Group.

CRM Cayman and MicroPort CardioFlow are working on the remaining steps towards completion of the Merger Agreement. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board  
**MicroPort Scientific Corporation**  
**Dr. Zhaohua Chang**  
*Chairman*

Shanghai, the PRC, 15 December 2025

*As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Dr. Feng Gu, Dr. Qingbing Men and Ms. Weiqin Sun; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.*

\* For identification purpose only